SynthesisWorld journal of surgical oncology2025
Prognostic significance of pretreatment systemic immune-inflammation index (SII) in patients with cervical cancer: a meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Specific diagnostic value of systemic immune-inflammation indices combined with nutritional and tumor markers in the stage diagnosis of pancreatic cancer: a retrospective cohort study.Frontiers in oncology · 2026Article
- Prognostic value of an integrated immune-inflammatory phenotype in surgically treated cervical cancer: survival modeling and immunohistochemical validation.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pretreatment systemic immune-inflammation index (SII) has been previously investigated for its potential in predicting the prognostic outcomes of cervical cancer (CC), but findings remain inconsistent. This meta-analysis aimed to clarify the prognostic value of SII in patients with CC.
methodsWeb of Science, PubMed, the Cochrane Library, and Embase databases were systematically searched up to October 15, 2025. The prognostic performance of SII in CC was evaluated by calculating pooled hazard ratios (HRs) and 95% confidence intervals (CIs). The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS).
resultsSixteen studies with a total of 2,840 patients were included. Fifteen studies comprising 2,735 cases were analyzed for OS, and nine studies including 1,349 patients were analyzed for PFS. Elevated SII was significantly associated with poorer OS (HR = 2.13, 95% CI = 1.60–2.85, p < 0.001) and PFS (HR = 1.81, 95% CI = 1.26–2.60, p < 0.001). Sensitivity analysis indicated stable results, confirming the robustness and reliability of the findings for both OS and PFS. No significant publication bias was detected according to Begg’s test.
conclusionsElevated pretreatment SII is significantly associated with poorer OS and reduced PFS in patients with CC. SII may serve as a reliable and efficient prognostic biomarker for CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.